Case Remain for Bal...
Health Care: Drugs
Novartis AG (NVS: NYSE)
$74.16 0.01 | 0.01%
05/20/13 - 04:02 PM ET
Growth Rates
| GROWTH RATES |
|---|
| REVENUE (Trailing 12 Quarters) |
| EARNINGS PER SHARE (Trailing 12 Quarters) |
| DIVIDENDS (Trailing 12 Quarters) |
Portfolios with NVS
- Portfolio NameUser Type
- Contributor9 Stocks to Buy for a Europ...
- Contributor8 High-Quality, Dividend-Pa...
- Userjohns7 Portfolio 1
- UserGFNN Stockdiagnostics 8
- ContributorTechnical Setups for the We...
- UserKAREL VON ZOETE
- UserMARIA DEL HUERTO
- ContributorHighest-Yielding Drug Stocks
- Userretirement
- ContributorLarge-Cap Dividend Stocks t...
Latest NVS Headlines from TheStreet
- 3 Stocks Pushing The Drugs Industry Higher 04.15.13 | 01:04 pm
- Novartis Reaches New 52-Week High (NVS) 04.10.13 | 10:04 am
- Novartis AG (NVS): Today's Featured Health Care Winner 04.08.13 | 05:04 pm
- Ariad CEO Strikes Back, Insists Leukemia Drug Is Fine 04.04.13 | 10:04 am
- The Survey Says: Ariad's Leukemia Drug Is Toxic 04.03.13 | 01:04 pm
- Stocks to Watch: Tesla, Verizon, Apple 04.03.13 | 05:04 am
- Novartis Reaches New 52-Week High (NVS) 04.02.13 | 10:04 am
- Morning Briefing: 10 Things You Should Know 04.01.13 | 07:04 am
- Biogen Wins FDA Approval of MS Pill 03.27.13 | 03:03 pm
- 4 Stocks Dragging The Drugs Industry Downward 03.27.13 | 01:03 pm
Press Releases for NVS
- Malaria No More Announces Innovative Partners For Its 'Power Of One' Malaria Campaign - PR Newswire 04.25.13 | 09:04 am
- University Teams Tap Mobile Phones And Social Networks To Fight Non-communicable Diseases - PR Newswire 02.09.12 | 04:02 pm
- IBM Launches University Competition To Combat Growth Of Non-Communicable Diseases - PR Newswire 10.07.11 | 03:10 pm
- ITG Healthcare Market Research Study Finds XGEVA On Track To Be Top-Prescribed Drug For Prevention Of SREs In Cancer Patients - PR Newswire 07.28.11 | 08:07 am
- ITG's Majestic Market Research Prostate Cancer Study Indicates Amgen's Xgeva Is Poised To Steal Significant Share From Novartis' Zometa; Physicians Still On The Fence About Dendreon's Provenge - PR Newswire 03.22.11 | 04:03 pm
Partner Headlines for NVS
- J&J Q1 Earnings Beat; Pharma Strong, Devices Weak - Investor's Business Daily 04.16.13 | 04:04 pm
- Four Dow Components Due for a Dividend Hike (CVX, XOM, IBM, JNJ) - Benzinga 04.04.13 | 12:04 pm
- Curing Parkinson's: The Alternative Approach - Is There Money To Be Made? - Seeking Alpha 04.04.13 | 09:04 am
- Will Novartis’s India Setback Bother These Top Institutional Shareholders? - Wall St. Cheat Sheet 04.01.13 | 12:04 pm
- Will Novartis’s India Setback Bother These Top Institutional Shareholders? - Wall St. Cheat Sheet 04.01.13 | 12:04 pm
- Analysts: CBS to Gain From Sports Ratings and 4 New Opinions Investors Must Take Note Of - Wall St. Cheat Sheet 04.01.13 | 11:04 am
- Analysts: CBS to Gain From Sports Ratings and 4 New Opinions Investors Must Take Note Of - Wall St. Cheat Sheet 04.01.13 | 11:04 am
- Will This Court Decision Be a Thorn in the Side of Novartis? - Wall St. Cheat Sheet 04.01.13 | 11:04 am
- Will This Court Decision Be a Thorn in the Side of Novartis? - Wall St. Cheat Sheet 04.01.13 | 11:04 am
- 10 Sharp Healthcare Dogs Diagnose 7.4% To 62.1% Gains In March - Seeking Alpha 04.01.13 | 09:04 am
